The global osteoarthritis drugs market size is expected to reach around US$ 11,226.1 Mn by the end of 2026. The global osteoarthritis drugs market is expected to be propel forward in the near future, thanks to a growing awareness of diseases like degenerative bone disease, increasing R&D, and growing geriatric population as well. The pharmaceutical industry is growing through a tough phase as several key patents have expired. On the other hand, the industry is also faced with opportunities to reduce manufacturing costs considerably, due to advancements like 3D printing, several lucrative outsourcing opportunities, and prospects like Nano technology. This is expected to act as a catalyst for innovation in the industry with several firms already raising the bar with new drug developments and vital modifications in processes.
The report analyzes and forecasts the osteoarthritis drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of osteoarthritis drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major osteoarthritis drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of osteoarthritis drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of osteoarthritis drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global osteoarthritis drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the osteoarthritis drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of osteoarthritis drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in the Report
The report also profiles major players operating in the global osteoarthritis drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics Inc., Ferring B.V., Bioventus Inc, Chugai Pharmaceutical Co. Limited, Alkem Laboratories, Flexion Therapeutics Inc., and Zimmer Biomet Holdings Inc.
The global osteoarthritis drugs market has been segmented as below:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Osteoarthritis Drugs Market
4. Market Overview
4.1. Overview
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2018–2026
4.4.1. Global Osteoarthritis Drugs Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1.Disease Prevalence & Incidence Rate globally with key countries
5.2.Regulatory Scenario by Region/globally
5.3.Pipeline Analysis
6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2018–2026
6.3.1. Corticosteroids
6.3.2. NSAIDs & others
6.3.3. Viscosupplementation Agents
6.4. Global Osteoarthritis Drugs Market Attractiveness by Drug Class
7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2018–2026
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration
8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2018–2026
8.3.1. Hospital pharmacies
8.3.2. Retail pharmacies
8.3.3. Online pharmacies
8.4. Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel
9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Osteoarthritis Drugs Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Osteoarthritis Drugs Market Attractiveness, by Region
10. North America Osteoarthritis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. North America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2018–2026
10.2.1.Corticosteroids
10.2.2. NSAIDs & Others
10.2.3.Viscosupplementation agents
10.3. North America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2018–2026
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. North America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2018–2026
10.4.1. Hospital pharmacies
10.4.2. Retail pharmacies
10.4.3. Online pharmacies
10.5. North America Osteoarthritis Drugs Market Value Forecast, by Country, 2018–2026
10.5.1. US
10.5.2. Canada
10.6. North America Osteoarthritis Drugs Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Osteoarthritis Drugs Market Analysis and Forecast
11.1.Introduction
11.2. Europe Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2018–2026
11.2.1. Corticosteroids
11.2.2. NSAIDs & Others
11.2.3. Viscosupplementation agents
11.3. Europe Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2018–2026
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Europe Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2018–2026
11.4.1. Hospital pharmacies
11.4.2. Retail pharmacies
11.4.3. Online pharmacies
11.5. Europe Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2018–2026
11.5.1. Germany
11.5.2. France
11.5.3. U.K.
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Osteoarthritis Drugs Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
12.1.Introduction
12.2. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2018–2026
12.2.1. Corticosteroids
12.2.2. NSAIDs & Others
12.2.3. Viscosupplementation agents
12.3. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2018–2026
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2018–2026
12.4.1. Hospital pharmacies
12.4.2. Retail pharmacies
12.4.3. Online pharmacies
12.5. Asia Pacific Osteoarthritis Drugs Market Value Forecast by Country/Sub-region, 2018–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
13.1.Introduction
13.2. Latin America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2018–2026
13.2.1. Corticosteroids
13.2.2. NSAIDs & Others
13.2.3. Viscosupplementation agents
13.3. Latin America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2018–2026
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Latin America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2018–2026
13.4.1. Hospital pharmacies
13.4.2. Retail pharmacies
13.4.3. Online pharmacies
13.5. Latin America Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2018–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Osteoarthritis Drugs Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
14.1.Introduction
14.2. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2018–2026
14.2.1. Corticosteroids
14.2.2. NSAIDs & Others
14.2.3. Viscosupplementation agents
14.3. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2018–2026
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Topical
14.4. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2018–2026
14.4.1. Hospital pharmacies
14.4.2. Retail pharmacies
14.4.3. Online pharmacies
14.5. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Country/Sub-regions, 2018–2026
14.5.1. GCC Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1. Global Osteoarthritis Drugs Market Player – Competition Matrix (by Tier and Size of companies)
15.2. Global Osteoarthritis Drugs Market Share Analysis, by Company (2018)
15.3. Company Profiles
15.3.1. Horizon Pharma plc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Anika Therapeutics, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ferring B.V.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bioventus, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Chugai Pharmaceutical Industries Limited
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Alkem Laboratories
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Flexion Therapeutics, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Zimmer Biomet Holdings, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers